Critical Review: ArQule (NASDAQ:ARQL) vs. Editas Medicine (EDIT) – The Lincolnian Online
|
Critical Review: ArQule (NASDAQ:ARQL) vs. Editas Medicine (EDIT)
The Lincolnian Online It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 … |
